市場調查報告書
商品編碼
1390485
2023-2028 年腸溶軟膠囊市場報告(按類型、應用、配銷通路和地區)Enteric Softgel Capsules Market Report by Type, Application, Distribution Channel, and Region 2023-2028 |
2022年全球腸溶軟膠囊市場規模達25億美元。展望未來, IMARC Group預計到2028年市場規模將達到32億美元,2022-2028年複合年成長率(CAGR)為4.20%。
腸溶軟膠囊具有基於明膠的外殼塗層,內部含有半固體和液體藥物。它們對消化液有抵抗力,因此可以不受影響地通過胃並溶解在腸道中。它們具有多種優點,例如生物利用度、易用性和提高的充分性水平。除此之外,它們還可以最大程度地減少不良餘味,最佳化劑量效率,幫助治療消化不良,並防止胃刺激和逆流。目前,人們對服用預防藥物的好處的認知不斷提高,刺激了全球對腸溶軟膠囊的需求。
全球老年人口的不斷成長,以及慢性疾病和營養缺乏性疾病盛行率的上升,是積極影響市場的關鍵因素之一。此外,個人健康意識的提高以及對營養和膳食補充劑的日益接受正在促進全球對腸溶軟膠囊的需求。除此之外,製藥業的顯著成長以及 Omega-3 油和其他凝膠補充劑產品應用的不斷擴大,帶來了良好的市場前景。此外,推出非明膠腸溶軟膠囊等產品創新正在加強市場的成長。此外,領先企業正專注於使用澱粉和其他有機植物來源來生產新品種,以滿足純素食消費者的需求。此外,藥局的不斷擴張以及透過電子商務零售管道的線上藥局的激增正在為市場創造積極的前景。此外,領先的製藥公司增加對研發(R&D)活動的投資以提高這些膠囊的生物利用度預計將推動市場成長。
The global enteric softgel capsules market size reached US$ 2.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2028, exhibiting a growth rate (CAGR) of 4.20% during 2022-2028.
Enteric softgel capsules have gelatin-based shell coating with semi-solid and liquid medication inside. They are resistant to digestive juices and consequently pass through the stomach unaffected and dissolve in the intestinal tract. They provide several advantages, such as bioavailability, easy usability, and improved adequacy levels. Besides this, they minimize poor aftertaste, optimize dosage efficiency, help treat indigestion, and prevent gastric irritation and reflux. Presently, the increasing awareness among individuals about the benefits of consuming preventive medicines is catalyzing the demand for enteric softgel capsules worldwide.
The growing global geriatric population, along with the rising prevalence of chronic medical disorders and nutrient-deficient diseases, represents one of the key factors positively influencing the market. In addition, the rising health awareness among individuals and the growing acceptance of nutritional and dietary supplements are catalyzing the demand for enteric softgel capsules across the globe. Besides this, significant growth in the pharmaceutical industry and the expanding applications of the product to enclose omega-3 oils and other gel-based supplements are offering a favorable market outlook. Additionally, product innovations like the introduction of non-gelatin-based enteric softgel capsules are strengthening the growth of the market. In addition, leading players are focusing on manufacturing novel variants by using starch and other organic, plant-based sources to meet the requirements of vegan consumers. Furthermore, the growing expansion of pharmacies and the proliferation of online pharmacies through e-commerce retail channels are creating a positive outlook for the market. Moreover, increasing investments by leading pharma companies in research and development (R&D) activities to improve the bioavailability of these capsules are expected to propel market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global enteric softgel capsules market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, application and distribution channel.
Gelatin Capsules
Non-Gelatin Softgel Capsules
Gelatin capsules currently represent the largest market segment due to the increasing vegan population across the globe.
Health Supplements
Pharmaceuticals
Health supplements hold the majority of the global enteric softgel capsules market share due to the increasing usage of softgel capsules by fitness enthusiasts and rising awareness among individuals about nutraceutical supplements.
Supermarkets and Hypermarkets
Pharmacy and Drug Stores
Online Stores
Pharmacy and drug stores presently dominate the market on account of the increasing consumer preference to purchase medicinal products from registered pharmacies or drug stores.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market as healthcare providers are increasingly investing in research and development (R&D) activities to introduce effective treatment alternatives.
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Some of these players are Aenova Group GmbH, BASF SE, Catalent, Inc., Colorcon Inc., Fuji Capsule Co., Ltd., Lonza Group AG, Now Health Group, Inc., ProCaps Group, Super Spectrim and Thermo Fisher Scientific, Inc.